An exact method for analysis following a two-stage phase II cancer clinical trial

Statistics in Medicine

Volumn 29, Issue 30, 2010, Pages 3118-3125

  Jovic, Gordana ^a   Whitehead, John ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Clinical trial; Exact method; Phase II; Two stage design

Indexed keywords

ACCURACY; ARTICLE; CANCER RESEARCH; CLINICAL TRIAL; DATA ANALYSIS; HUMAN; MATHEMATICAL ANALYSIS; METHODOLOGY; PHASE 2 CLINICAL TRIAL; PROBABILITY; RESEARCH ETHICS; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE II AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; MEDICAL ONCOLOGY; ODDS RATIO; RESEARCH DESIGN;

EID: 78650239326     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3837     Document Type: Article

References (20)

1. Judson I. Evaluation of new anti-cancer drugs. In Oncology: A Multidisciplinary Textbook. Horwich A (ed.). Chapman & Hall: London, 1995;147159.
2. Green SJ, Dahlberg S. Planned versus attained design in phase II clinical trial. Statistics in Medicine 1992; 11:853862.
3. A'Hern RP. Sample size table for exact single-stage phase II trials. Statistics in Medicine 2001; 20:859866. DOI: 10.1002/sim.721.
4. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26:404413. DOI: 10.1093/biomet/26.4.404.
5. Simon R. Optimal two-stage design for phase II clinical trials. Controlled Clinical Trials 1989; 10:110. DOI: 10.1016/0197-2456(89)90015-9.
6. Fleming RT. One-sample multiple testing procedures for phase II clinical trials. Biometrics 1982; 38:143151.
7. Koyama T, Chen H. Proper inference from Simon's two-stage design. Statistics in Medicine 2008; 27:31453154. DOI: 10.1002/sim.3123.
8. Tsai W-Y, Chi Y, Chen C-M. Interval estimation of binomial proportion in clinical trials with a two-stage design. Statistics in Medicine 2008; 27:1535. DOI: 10.1002/sim.2930.
9. Whitehead J. The Design and Analysis of Sequential Clinical Trials. Revised (2nd edn). Wiley: Chichester, 1997.
10. Fairbanks K, Madsen R. P-values for tests using a repeated significance test design. Biometrika 1982; 69:6974. DOI: 10.1093/biomet/69.1.69.
11. SAS. Available from: .
12. Dodge HF, Romig HG. A method of sampling inspection. The Bell System Technical Journal 1929; 8:613631.
13. Chang MN, Therneau TM, Weiand HS, Cha SS. Designs for group sequential phase II clinical trials. Biometrics 1987; 43:865874.
14. Chen S, Soong S-J, Wheeler RH. An efficient multiple-stage procedure for phase II clinical trials that have high response rate objectives. Controlled Clinical Trials 1994; 15:277283.
15. Chen TT. Optimal three-stage designs for phase II cancer clinical trials. Statistics in Medicine 1997; 16:27012711. DOI: 10.1002/(SICI)1097-0258(19971215) 16:23<2701::AID-SIM704>3.0.CO;2-1.
16. Bellisant E, Benichou J, Chastang C. Application of the triangular test to phase II cancer clinical trials. Statistics in Medicine 1990; 9:907917. DOI: 10.1002/sim.4780090807.
17. Lin SP, Chen TT. Optimal two-stage designs for phase II clinical trials with differentiation of complete and partial responses. Communications in Statistics, Part A-Theory and Methods 2000; 29:923940. DOI: 10.1080/03610920008832524.
18. Panageas KH, Smith A, Gönen M, Chapman PB. An optimal two-stage phase II design utilizing complete and partial response information separately. Controlled Clinical Trials 2002; 23:367379. DOI: 10.1016/S0197-2456(02)00217-9.
19. Lu Y, Jin H, Lamborn KR. A design of phase II cancer trials using total and complete response endpoints. Statistics in Medicine 2005; 24:31553170. DOI: 10.1002/sim.2188.
20. Agresti A, Coull BA. Approximate is better than 'exact' for interval estimation of binomial proportions. The American Statistician 1998; 52(2):119126. DOI: 10.2307/2685469.